Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE5A | O76074 | 20/20 | 0.84 |
| ▸ | PDE3B | Q13370 | 3/20 | 0.65 |
| ▸ | PDE3A | Q14432 | 3/20 | 0.65 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.65 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.65 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.65 |
| ▸ | ABCC4 | O15439 | 2/20 | 0.62 |
| ▸ | PDE2A | O00408 | 1/20 | 0.62 |
| ▸ | ABCC5 | O15440 | 1/20 | 0.62 |
| ▸ | PDE6D | O43924 | 1/20 | 0.62 |
| ▸ | PDE8A | O60658 | 1/20 | 0.62 |
| ▸ | PDE9A | O76083 | 1/20 | 0.62 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.62 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.62 |
| ▸ | HTR1A | P08908 | 1/20 | 0.62 |
| ▸ | PDE6A | P16499 | 1/20 | 0.62 |
| ▸ | PDE6G | P18545 | 1/20 | 0.62 |
| ▸ | PDE4A | P27815 | 1/20 | 0.62 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.62 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.62 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23937345 | 1.00 | PDE5A (0.84) | PDE5APDE3BPDE3AHDAC1HDAC6 | |
| SCHEMBL21705396 | 1.00 | PDE5A (0.84) | PDE5APDE3BPDE3AHDAC1HDAC6 | |
| SCHEMBL21705362 | 0.94 | PDE5A (0.81) | PDE5APDE3BPDE3AHDAC1HDAC6 | |
| SCHEMBL21705159 | 0.94 | PDE5A (0.81) | PDE5APDE3BPDE3AHDAC1HDAC6 | |
| SCHEMBL29601426 | 0.94 | PDE5A (0.81) | PDE5APDE3BPDE3AHDAC1HDAC6 | |
| SCHEMBL21682533 | 0.90 | PDE5A (0.95) | PDE5APDE3BPDE3AHDAC1HDAC6 | |
| SCHEMBL29601486 | 0.90 | PDE5A (0.95) | PDE5APDE3BPDE3AHDAC1HDAC6 | |
| SCHEMBL23937271 | 0.89 | PDE5A (0.81) | PDE5APDE3BPDE3AHDAC1HDAC6 | |
| SCHEMBL23370668 | 0.89 | PDE5A (0.68) | PDE5APDE3BPDE3AHDAC1HDAC6 | |
| SCHEMBL23937390 | 0.89 | PDE5A (0.82) | PDE5APDE3BPDE3AHDAC1HDAC6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230414621-A1 | NO-PDE5 INHIBITOR FOR USE IN TREATING DRY AGE-RELATED MACULAR DEGENERATION, GEOGRAPHIC ATROPHY AND GLAUCOMA-ASSOCIATED NEURODEGENERATION | NICOX S.A. (FR) | 2023-12-28 | — | — | US | claimed |
| EP-4236952-A1 | NO-PDE5 INHIBITOR FOR USE IN TREATING DRY AGE-RELATED MACULAR DEGENERATION, GEOGRAPHIC ATROPHY AND GLAUCOMA-ASSOCIATED NEURODEGENERATION | Nicox S.A. (FR) | 2023-09-06 | — | — | EP | claimed |
| WO-2022090379-A1 | NO-PDE5 INHIBITOR FOR USE IN TREATING DRY AGE-RELATED MACULAR DEGENERATION, GEOGRAPHIC ATROPHY AND GLAUCOMA-ASSOCIATED NEURODEGENERATION | NICOX S.A. (FR) | 2022-05-05 | — | — | WO | claimed |
| US-20240245684-A1 | NITRIC OXIDE RELEASING PHOSPHODIESTERASE TYPE 5 INHIBITOR | NICOX S.A. (FR) | 2024-07-25 | — | — | US | disclosed |
| US-20230414621-A1 | NO-PDE5 INHIBITOR FOR USE IN TREATING DRY AGE-RELATED MACULAR DEGENERATION, GEOGRAPHIC ATROPHY AND GLAUCOMA-ASSOCIATED NEURODEGENERATION | NICOX S.A. (FR) | 2023-12-28 | — | — | US | disclosed |
| EP-4236952-A1 | NO-PDE5 INHIBITOR FOR USE IN TREATING DRY AGE-RELATED MACULAR DEGENERATION, GEOGRAPHIC ATROPHY AND GLAUCOMA-ASSOCIATED NEURODEGENERATION | Nicox S.A. (FR) | 2023-09-06 | — | — | EP | disclosed |
| WO-2022090379-A1 | NO-PDE5 INHIBITOR FOR USE IN TREATING DRY AGE-RELATED MACULAR DEGENERATION, GEOGRAPHIC ATROPHY AND GLAUCOMA-ASSOCIATED NEURODEGENERATION | NICOX S.A. (FR) | 2022-05-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230414621-A1 | NO-PDE5 INHIBITOR FOR USE IN TREATING DRY AGE-RELATED MACULAR DEGENERATION, GEOGRAPHIC ATROPHY AND GLAUCOMA-ASSOCIATED NEURODEGENERATION | PDE5A, PDE2A, PDE3A | PDE5A 1/4885PDE3B 4/4885PDE3A 3/4885 |
| US-20240245684-A1 | NITRIC OXIDE RELEASING PHOSPHODIESTERASE TYPE 5 INHIBITOR | PDE5A, PDE3A, PDE6A | PDE5A 1/4885PDE3B 6/4885PDE3A 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.